Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults >75 years (EU-COVAT-1)

被引：5

作者：

Neuhann, Julia M. ^{[1
,2
,3
,4
,5
,6
]}

Stemler, Jannik ^{[1
,2
,3
,4
,5
,6
]}

Carcas, Antonio J. ^{[7
]}

Frias-Iniesta, Jesus ^{[7
]}

Akova, Murat ^{[8
]}

Bethe, Ullrich ^{[1
,2
,3
,4
,5
,6
]}

Heringer, Sarah ^{[1
,2
,3
,4
,5
,6
]}

Salmanton-Garcia, Jon ^{[1
,2
,3
,4
,5
,6
]}

Tischmann, Lea ^{[1
,2
,3
,4
,5
,6
]}

Zarrouk, Marouan ^{[1
,2
,4
,5
]}

Cueppers, Arnd ^{[9
]}

Grothe, Jan ^{[1
,2
,3
,4
,5
,6
]}

Leon, Alejandro Garcia ^{[10
]}

Mallon, Patrick ^{[10
]}

Negi, Riya ^{[10
]}

Gaillard, Colette ^{[10
]}

Saini, Gurvin ^{[10
]}

Lammens, Christine ^{[11
,12
]}

Hotterbeekx, An ^{[13
,14
]}

Loens, Katherine ^{[11
,12
]}

Malhotra-Kumar, Surbhi ^{[11
,12
]}

Goossens, Herman ^{[11
,12
]}

Kumar-Singh, Samir ^{[13
,14
]}

Koenig, Franz ^{[15
]}

Yeghiazaryan, Lusine ^{[15
]}

Posch, Martin ^{[15
]}

Koehler, Philipp ^{[1
,2
,3
,4
,5
]}

Cornely, Oliver A. ^{[1
,2
,3
,4
,5
,6
,9
,16
]}

机构：

[1] Univ Cologne, Fac Med, Herderstr 52, D-50931 Cologne, Germany

[2] Univ Hosp Cologne, Translat Res, Cologne Excellence Cluster Cellular Stress Respons, Herderstr 52, D-50931 Cologne, Germany

[3] Univ Cologne, Fac Med, Kerpener Str 62, D-50937 Cologne, Germany

[4] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany

[5] Excellence Ctr Med Mycol ECMM, Kerpener Str 62, D-50937 Cologne, Germany

[6] German Ctr Infect Res DZ, Partner Site Bonn Cologne Dept, Herderstr 52, D-50931 Cologne, Germany

[7] Univ Autonoma Madrid, Hosp La Paz, Inst Hlth Res IdiPAZ, Fac Med, Madrid, Spain

[8] Hacettepe Univ, Sch Med, Dept Infect Dis, Ankara, Turkiye

[9] Univ Cologne, Fac Med, Clin Trials Ctr Cologne CTCC Cologne, Gleueler Str 269, D-50935 Cologne, Germany

[10] Univ Coll Dublin, UCD Ctr Expt Pathogen Host Res CEPHR, Sch Med, Dublin, Ireland

[11] Univ Antwerp, Vaccine & Infect Dis Inst, Lab Med Microbiol LMM, Antwerp, Belgium

[12] Univ Antwerp, Biobank Antwerp, Antwerp, Belgium

[13] Univ Antwerp, Fac Med, Lab Cell Biol & Histol, Mol Pathol Grp, Antwerp, Belgium

[14] Univ Antwerp, Vaccine & Infect Dis Inst CBH, Fac Med, Antwerp, Belgium

[15] Med Univ Vienna, Ctr Med Data Sci, Spitalgasse 23, A-1090 Vienna, Austria

[16] CECAD Translat Res, Herderstr 52, D-50931 Cologne, Germany

来源：

VACCINE | 2023年 / 41卷 / 48期

关键词：

Belgium; SARS-CoV-2; Advanced age; Third dose; Variants of concern; Anti-RBD IgG; Neutralising antibodies; VACCINATION;

D O I：

10.1016/j.vaccine.2023.10.029

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: Vaccination remains crucial for protection against severe SARS-CoV-2 infection, especially for people of advanced age, however, optimal dosing regimens are as yet lacking.Methods: EU-COVAT-1-AGED Part A is a randomised controlled, adaptive, multicentre phase II trial evaluating safety and immunogenicity of a 3rd vaccination (1st booster) in individuals >= 75 years. Fifty-three participants were randomised to full-doses of either mRNA-1273 (Spikevax (R), 100 mu g) or BNT162b2 (Comirnaty (R), 30 mu g). The primary endpoint was the rate of 2-fold circulating antibody titre increase 14 days post-vaccination measured by quantitative electrochemiluminescence (ECL) immunoassay, targeting RBD region of Wuhan wild-type SARS-CoV-2. Secondary endpoints included the changes in neutralising capacity against wild-type and 25 variants of concern at 14 days and up to 12 months. Safety was assessed by monitoring of solicited adverse events (AEs) for seven days after on-study vaccination. Unsolicited AEs were collected until the end of follow-up at 12 months, SAEs were pursued for a further 30 days.Results: Between 08th of November 2021 and 04th of January 2022, 53 participants >= 75 years received a COVID-19 vaccine as 1st booster. Fifty subjects (BNT162b2 n = 25/mRNA-1273 n = 25) were included in the analyses for immunogenicity at day 14. The primary endpoint of a 2-fold anti-RBD IgG titre increase 14 days after vaccination was reached for all subjects. A 3rd vaccination of full-dose mRNA-1273 provided higher anti-RBD IgG titres (Geometric mean titre) D14 mRNA-127310711 IU/mL (95 %-CI: 8003;14336) vs. BNT162b2: 7090 IU/mL (95 %-CI: 5688;8837). We detected a pattern showing higher neutralising capacity of full-dose mRNA-1273 against wild-type as well as for 23 out of 25 tested variants.Interpretation: Third doses of either BNT162b2 or mRNA-1273 provide substantial circulating antibody increase 14 days after vaccination. Full-dose mRNA-1273 provides higher antibody levels with an overall similar safety profile for people >= 75 years.

引用

页码：7166 / 7175

页数：10

共 47 条

[21] Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults
Dedroogh, Simon
Schmiedl, Sven
Thuermann, Petra A.
Graf, Katharina
Appelbaum, Sebastian
Koss, Reinhard
Theis, Christian
Zia, Zewarudin
Tebbenjohanns, Juergen
Thal, Serge C.
Dedroogh, Michael
SCIENTIFIC REPORTS, 2023, 13 (01)
[22] Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens
Klemis, Verena
Schmidt, Tina
Schub, David
Mihm, Janine
Marx, Stefanie
Abu-Omar, Amina
Ziegler, Laura
Hielscher, Franziska
Guckelmus, Candida
Urschel, Rebecca
Wagenpfeil, Stefan
Schneitler, Sophie
Becker, Soeren L.
Gaertner, Barbara C.
Sester, Urban
Sester, Martina
NATURE COMMUNICATIONS, 2022, 13 (01)
[23] Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults
Sun, Tianyu
Li, Linwei
Mues, Katherine E.
Georgieva, Mihaela V.
Kirk, Brenna
Mansi, James A.
van de Velde, Nicolas
Beck, Ekkehard C.
INFECTIOUS DISEASES AND THERAPY, 2024, 13 (08) : 1771 - 1787
[24] Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens
Verena Klemis
Tina Schmidt
David Schub
Janine Mihm
Stefanie Marx
Amina Abu-Omar
Laura Ziegler
Franziska Hielscher
Candida Guckelmus
Rebecca Urschel
Stefan Wagenpfeil
Sophie Schneitler
Sören L. Becker
Barbara C. Gärtner
Urban Sester
Martina Sester
Nature Communications, 13
[25] Immunogenicity, safety, and reactogenicity of a halfversus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
Batmunkh, Tsetsegsaikhan
Moore, Kerryn A.
Thomson, Helen
Altangerel, Bolor
Amraa, Otgonjargal
Avaa, Naranbaatar
Batbayar, Lkhagvagaram
Batsukh, Khishigjargal
Bright, Kathryn
Burentogtokh, Tsogjargal
Do, Lien Anh Ha
Dorj, Gantuya
Hart, John D.
Javkhlantugs, Khulan
Jigjidsuren, Sarantsetseg
Justice, Frances
Li, Shuo
V. Licciardi, Paul
Mashbaatar, Khaliunaa
Mazarakis, Nadia
Neal, Eleanor F. G.
Nguyen, Cattram Duong
Ochirbat, Batbayar
Tsolmon, Bilegtsaikhan
Tuya, Alimaa
Surenjav, Unursaikhan
von Mollendorf, Claire
Mulholland, Kim
LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 42
[26] Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
Vivaldi, Giulia
Jolliffe, David A.
Holt, Hayley
Tydeman, Florence
Talaei, Mohammad
Davies, Gwyneth A.
Lyons, Ronan A.
Griffiths, Christopher J.
Kee, Frank
Sheikh, Aziz
Shaheen, Seif O.
Martineau, Adrian R.
LANCET REGIONAL HEALTH-EUROPE, 2022, 22
[27] Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial (vol 398, pg 121, 2021)
Borobia, A. M.
Carcas, A. J.
Perez-Olmeda, M.
LANCET, 2021, 398 (10300): : 582 - 582
[28] A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
Julia M. Neuhann
Jannik Stemler
Antonio Carcas
Jesús Frías-Iniesta
Ullrich Bethe
Sarah Heringer
Lea Tischmann
Marouan Zarrouk
Arnd Cüppers
Franz König
Martin Posch
Oliver A. Cornely
Trials, 23
[29] Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?
Favresse, Julien
Tre-Hardy, Marie
Gillot, Constant
Cupaiolo, Roberto
Wilmet, Alain
Beukinga, Ingrid
Blairon, Laurent
Bayart, Jean-Louis
Closset, Melanie
Wauthier, Loris
Cabo, Julien
David, Clara
Elsen, Marc
Dogne, Jean-Michel
Douxfils, Jonathan
HELIYON, 2024, 10 (16)
[30] A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
Neuhann, Julia M.
Stemler, Jannik
Carcas, Antonio
Frias-Iniesta, Jesus
Bethe, Ullrich
Heringer, Sarah
Tischmann, Lea
Zarrouk, Marouan
Cueppers, Arnd
Koenig, Franz
Posch, Martin
Cornely, Oliver A.
TRIALS, 2022, 23 (01)

← 1 2 3 4 5 →

Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults &gt;75 years (EU-COVAT-1)

Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults >75 years (EU-COVAT-1)